Mirum Pharmaceuticals (NASDAQ:MIRM) vs. Spyre Therapeutics (NASDAQ:SYRE) Head to Head Review

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk and Volatility

Spyre Therapeutics has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.

Profitability

This table compares Spyre Therapeutics and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spyre Therapeutics N/A -35.97% -27.67%
Mirum Pharmaceuticals -134.75% -97.25% -12.59%

Valuation and Earnings

This table compares Spyre Therapeutics and Mirum Pharmaceuticals”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spyre Therapeutics $890,000.00 10,629.06 -$155.20 million ($2.74) -36.35
Mirum Pharmaceuticals $521.31 million 11.55 -$23.36 million ($15.47) -5.96

Mirum Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Spyre Therapeutics and Mirum Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics 1 1 13 2 2.94
Mirum Pharmaceuticals 1 0 13 1 2.93

Spyre Therapeutics presently has a consensus price target of $110.53, indicating a potential upside of 10.97%. Mirum Pharmaceuticals has a consensus price target of $155.56, indicating a potential upside of 68.70%. Given Mirum Pharmaceuticals’ higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Spyre Therapeutics.

Insider & Institutional Ownership

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Spyre Therapeutics beats Mirum Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin ?4?7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.